Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming Thomas Byrne .
Filed returns
12
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2026 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicine (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness, pharmaceutical manufacturing, and EU-level health emergency preparedness (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | EU Affairs | Ireland priorities for the Presidency of the Council of the European Union (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Economic Development and Industry | Proposed COVID-19 Trips waiver (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | EU Affairs | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) | 8 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | EU Affairs | Highlight Pfizer concerns re proposed EU vaccine export restrictions and how this could impact Pfizer's ability to manufacture the COVID 19 vaccine and provide supply globally (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 6 | 50.0% | |
| EU Affairs | 5 | 41.7% | |
| Economic Development and Industry | 1 | 8.3% |